-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BUKQ2PTtDhFQuAKVwVDvxkqovIIlWzyYP9N2nqpJOSpRxTMZ4zGgYpw+NdMXHK2d
 00PwBg9YP2NdSIgaNJESFw==

<SEC-DOCUMENT>0001188112-10-001753.txt : 20100706
<SEC-HEADER>0001188112-10-001753.hdr.sgml : 20100705
<ACCEPTANCE-DATETIME>20100706161929
ACCESSION NUMBER:		0001188112-10-001753
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20100629
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100706
DATE AS OF CHANGE:		20100706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		10939139

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t68466_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>t68466_8k.htm</title>
<!-- Licensed to: TriState Financial-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">FORM 8-K</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT REPORT</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of report (Date of earliest event reported): June 29, 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied DNA Sciences, Inc</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact Name of Registrant as Specified in Charter)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Delaware</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State or Other Jurisdiction</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of Incorporation)</font></div>
</td>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">002-90539</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission File Number)</font></div>
</td>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">59-2262718</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS Employer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25 Health Sciences Drive, Suite 113</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stony Brook, New York 11790</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of Principal Executive Offices) (Zip Code)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">631-444- 8090</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not Applicable</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former Name or Former Address, if Changed Since Last Report)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 5.02.&#160;&#160;Departure or Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;On July 1, 2010, the Board of Directors of Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) granted nonstatutory stock options under the Company&#8217;s 2005 Incentive Stock Plan to the Company&#8217;s <font style="DISPLAY: inline">principal executive officer, principal financial officer and one other named executive officer</font> (the &#8220;executive officers&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company will enter into an employee nonstatutory stock option agreement with each of the executive officers:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Award Type</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number of Awards</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercise Price</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Award Plan</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">James A. Hayward</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nonstatutory Stock Options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10,000,000</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$0.06</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2005 Incentive Stock Plan</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Kurt H. Jensen</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nonstatutory Stock Options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10,000,000</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$0.06</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2005 Incentive Stock Plan</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ming-Hwa Liang</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nonstatutory Stock Options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10,000,000</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$0.06</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2005 Incentive Stock Plan</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The options granted to the executive officers vested with respect to 25% of the underlying shares on the date of grant, and the remaining will vest ratably each anniversary thereafter until fully vested on the third anniversary of the date of grant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 8.01.&#160;&#160;Other Events.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">On June 29, 2010, the Company issued a press release to announce that it has customized its first series of &#8220;DNA Suits&#8221; made in Yorkshire, UK.&#160;&#160;</font>A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 6, 2010, the Company issued a press release to announce that it has entered into an agreement with H.W. Sands Corp. (&#8220;HW Sands&#8221;) whereby the Company and HW Sands will jointly market and sell DNA security-based solutions to clients.&#160;&#160;A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 9.01.&#160;&#160;Financial Statements and Exhibits.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 63pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibits</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%" style="BORDER-RIGHT: black 1px solid; BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid; BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
<td valign="bottom" width="70%" style="BORDER-RIGHT: black 1px solid; BORDER-TOP: black 1px solid; BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release of Applied DNA Sciences, Inc., dated June 29, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-RIGHT: black 1px solid; BORDER-LEFT: black 1px solid; BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.2</font></div>
</td>
<td valign="bottom" width="70%" style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release of Applied DNA Sciences, Inc., dated July 6, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>



<div>&#160;</div>

<div style="TEXT-ALIGN: left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="89%" style="TEXT-ALIGN: left; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: left;">
<td width="56%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Applied DNA Sciences, Inc.</font></font></td>
</tr><tr>
<td width="56%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></td>
</tr><tr>
<td width="56%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="56%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="56%" style="PADDING-BOTTOM: 2px"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ James A. Hayward&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font></td>
</tr><tr>
<td width="56%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James A. Hayward</font></td>
</tr><tr>
<td width="56%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="44%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: July 6, 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT INDEX</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Description</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press Release of Applied DNA Sciences, Inc., dated June 29, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.2</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press Release of Applied DNA Sciences, Inc., dated July 6, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
<!-- Licensed to: TriState Financial-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 99.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><img src="img001.jpg" alt="GRAPHIC"></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied DNA Sciences Earns Its Stripes --</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Textile-based SigNature DNA Anti-Counterfeiting Program Launched in UK</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STONY BROOK, N.Y., June 29, 2010 /Market Wire/ -- Applied DNA Sciences, Inc. (OTCBB:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">APDN), a provider of DNA-based security solutions announced that it has successfully </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">customized its first series of &#8220;DNA Suits&#8221; made in Yorkshire, UK. Each DNA suit was custommade from the finest woolen yarn, then woven and finished into a pinstripe fabric, and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">assembled by a master tailor. The DNA persists through multiple launderings, providing a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">definitive means to match the DNA mark to the bespoke suit. Importa
nt to the utility of this </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">marker to textile manufacturers, finishers and woven label assemblers, is that no retooling or </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">change in production methods is required &#8211; integration of DNA in manufacturing is seamless.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bill Macbeth, the Managing Director of the Textile Centre of Excellence stated, &#8220;DNA represents </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an important step in the evolution of our industry &#8211; both for existing processes and new</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">products, as well as providing a tangible means to stimulate manufacturing jobs in our region. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We believe that the exceptional quality and craftsmanship that Yorkshire companies pride</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">themselves on from yarn to woven fabric to a garment label, are valuable and worth protecting. </font><font style="DISPLAY: inline; FON
T-SIZE: 10pt; FONT-FAMILY: Times New Roman">We see Yorkshire as taking a technology leadership position by elevating the standard of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">textiles made in Yorkshire and demonstrating that you do get superior garments when you can control the quality of the fabric itself.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of the launch of the DNA Anti-Counterfeiting Program, APDN has received its first order </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">from the Textile Centre of Excellence as part of its participation in the multi-year contract funded </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">by the European Regional Development Fund and Yorkshire Forward. The initiating order </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(approximately $50,000) commences a three-year commitment of government of $1,500,000 to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the program. &#8220;This contribution is designed to generate significant additional investment from </font><font style="DISPLAY: inline; FONT
- -SIZE: 10pt; FONT-FAMILY: Times New Roman">the private sector, which should generate at least 2 million pounds over the three-year lifetime of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the program,&#8221; stated Bill Macbeth, Managing Director, Textile Centre of Excellence. APDN is </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">working with local companies to incorporate its botanical SigNature DNA markers into their </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">products to protect premium textiles and apparel from counterfeiting and diversion, offering end-consumers with complete confidence in their purchases.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recently, a bespoke men's jacket made by exclusive tailor, James Michelsberg was treated with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SigNature DNA creating a unique "fingerprint" to prove its authenticity. The fibers for the cloth </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">used to make the suit were immersed in SigNature DNA as they were put on the loom, before </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the fabric was finished. Mr. Michelsberg was recently quoted in The Yorkshire Evening Post as </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">saying: "Counterfeiting is the biggest problem facing the textiles industry. There are people in </font><font style="DISPLAY: inline; FONT
- -SIZE: 10pt; FONT-FAMILY: Times New Roman">India and China counterfeiting cloth, saying it&#8217;s woven in Yorkshire. We want to make sure </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">they&#8217;re (customers) getting the genuine article.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Andrew Knight from luxury weaver, John Cavendish, added, &#8220;It's tremendously exciting. With </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DNA you get authenticity, genuine goods and traceability - you can trace it back to the raw </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">material, who wove it, who finished it and who sold the fabric. It's absolutely fantastic. As a local company it's something the industry has been crying out for."</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Authentication issues plague the global economy. From high-tech synthetic yarns to wool </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">fabrics, from cotton bed linen to outdoor fabrics and treatments, to &#8220;haute couture&#8221; fabric, the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">growth of counterfeiting is doubling the pace of total apparel market growth. Of the total value of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">counterfeit merchandise seized around the world, 63% related to the textile sector. According to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Global Market Report on Counterfeit Apparel (2008), industry analysts expect the proportion </font><font style="DISP
LAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of counterfeiting in certain sectors to roughly double in the 2005 to 2014 period. In a multi-billion </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">dollar market, this is not a small problem. The UK textile and clothing industry, the 9<font style="DISPLAY: inline; FONT-SIZE: 10pt">th </font>largest </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">manufacturing sector in the UK, generates over &#163;18 billion/year in revenues. In the US, textile </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and apparel is the third largest exporter and represents at least $90 billion in revenues per year. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">APDN is offering the best and most cost effective solution to-date, a solution that cannot be </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New R
oman">copied, reverse engineered or otherwise compromised.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Whether it is the finest worsted wools from Yorkshire, super fine merino from Australia, pure </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cashmere, or recycled polyester the demand to protect the integrity and authenticity of products </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">at the source is growing and we are very pleased to be able to provide a practical solution to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">address this most pressing need,&#8221; commented Dr. James Hayward, President and CEO of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">APDN. &#8220;Applied DNA has now truly earned its stripes.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About APDN</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">APDN sells patented DNA security solutions to protect products, brands and intellectual </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">property from counterfeiting and diversion. SigNature DNA is a botanical mark used to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">authenticate products in a unique manner that essentially cannot be copied. APDN also </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">provides BioMaterial GenoTyping&#8482; by detecting genomic DNA in natural materials to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">authenticate finished products. Both technologies protect brands and products in a wide range </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of industries and provide a forensic chain of evidence that can be used to prosecute</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">perpetrators. To learn more, go to <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.adnas.com</font> where APDN routinely posts all press </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">releases.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The statements made by APDN may be forward-looking in nature and are made pursuant to the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">statements describe APDN&#8217;s future plans, projections, strategies and expectations, and are </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">based on assumptions and involve a number of risks and uncertainties, many of which are </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">beyond the control of APDN. Actual results could differ materially from those projected due to </font><font style="DISPLAY: inline; FONT-SIZE: 
10pt; FONT-FAMILY: Times New Roman">our short operating history, limited financial resources, limited market acceptance, market </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">competition and various other factors detailed from time to time in APDN&#8217;s SEC reports and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">filings, including our Annual Report on Form 10-K, filed on December 23, 2009 and our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">any forward-looking statements to reflect new information, events or circumstances after the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">date hereof to reflect the occurrence of unanticipated events.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SOURCE Applied DNA Sciences, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">FCMN Contact: </font><font style="DISPLAY: inline; COLOR: #65659b; TEXT-DECORATION: underline">info@adnas.com</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Web site: http://www.adnas.com</font></div>
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
<head>
    <title>ex99-2.htm</title>
<!-- Licensed to: TriState Financial-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 99.2</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><img src="img001.jpg" alt="GRAPHIC"></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied DNA Sciences and H.W. Sands Corp. Sign Agreement to Jointly Market Security Technologies</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STONY BROOK, N.Y., July 6, 2010 /Market Wire/ -- Applied DNA Sciences, Inc. (OTC BB: APDN), a provider of DNA-based security solutions, and H.W. Sands Corp., a trusted leader in the global market for advancing security, chemical and card industries, announced the signing of an Agreement to jointly market and sell DNA security-based solutions to clients that are dedicated to protecting their products, supply chains and end consumers from counterfeiting and gray market diversion.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">H.W. Sands Corp. has grown to be a trusted leader in the global marketplace since 1983; doing business in more than 30 countries with a distribution network in Japan, China, Korea and Europe. Recently, H.W. Sands Corp. launched a new division in response to the increased demand for security inks and dyes, with the inclusion of DNA as the definitive means for authentication. With its own dedicated team focused on the growing need for the best-in-breed security solutions, H.W. Sands Security will be working with APDN to jointly market and sell forensic DNA markers and authentication services in targeted industry verticals. H.W. Sands Security is currently in negotiations with potential distributors in Brazil, South America, Australia and India. H.W. Sands currently has existing distributors for Japan, China, Korea and Europe. The company&#8
217;s expertise is in the manufacture of a variety of dyes, inks, and chemical solutions for screen, gravure and flexographic printing. They service Fortune 100 and 500 clients all over the world and renowned for their high quality custom dyes and inks used in hundreds of millions products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;We are all about delivering outstanding value to our customers by offering best-in-breed DNA technology that secures brand and inspires consumer confidence. With more uncertainty as to whether products are truly genuine, comes the opportunity to provide the most secure and interactive packaging and documentation available on the market. That&#8217;s why partnering with Applied DNA Sciences makes perfect sense. There is no doubt in my mind that forensic level marking and authentication will soon become an essential component in brand management,&#8221; stated Jeffrey Strahl, Vice President, H.W .Sands Security; the security division of H.W. Sands Corp.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Our sales and marketing reach is greatly enhanced by our partnership with H.W. Sands Corp. They have significant expertise and reach in multiple industry verticals that complement our efforts, and also expand our growth and market penetration in Asia and abroad,&#8221; commented James A. Hayward, CEO of APDN.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About H.W. Sands</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">H. W. Sands Corp. is a worldwide leader in the design and manufacture of products for the Imaging Industry with a primary focus on the Security, Transaction Card, Electrophotographic, Display/OLED, Ink Jet and Pre-sensitized Printing Plate markets. Established in 1983, H.W. Sands Corp. provides research, development and commercialization of high-value, custom and commercial dyes, chemicals and corollary products that support customers&#8217; product differentiation, thereby increasing brand value and overall profitability. H.W. Sands Corp. is headquartered in Jupiter, Florida and for more information, visit<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; COLOR: #0000ff; TEXT-DECORATION: underline">www.hwsands.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About APDN</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping&#8482; by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to (</font><font style="DISPLAY: inline; COLOR: #000080; TEXT-DECORATION: underline">www.adnas.com</font><font style="DISPLAY: inline">).</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN&#8217;s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN&#8217;s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 23, 2009 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looki
ng statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SOURCE Applied DNA Sciences, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FCMN Contact: info@adnas.com</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Web site: http://www.adnas.com</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!,`>8#`2(``A$!`Q$!_\0`
M'0```00#`0$```````````````4&!P@!`P0""?_$`%,0``$#`P(#!00#"0@0
M!P````$"`P0`!1$&$@<A,0@305%A%"(R<16!TA870E)6<I&ALR-#8I.4E:/B
M)2@U-C<X57-T=8*2L;3!T3-3A**R\/'_Q``9`0$``P$!````````````````
M`0($`P7_Q``Q$0`"`@$"`@<&!P$``````````0(#$002(3$3%")!4F&!,E%Q
MDJ'P0U-RD;'1X<'_V@`,`P$``A$#$0`_`+4T444`4444`4444`4444`4444`
M4444`4444`4444`4444`44&L9H#-%8S6:`****`****`****`****`****`*
M***`****`****`****`****`****`****`**9/$CB;IKA_%*K[.2)BVBXQ":
M!6\]UQR'P@D8"E8'7G53^(G:,U9JEE42T)1IZ#N!S$=49!]W!!=Y<LY/NI2?
M4T!;C5W$C1^D2M&H+_"BOI.%1TJ+KP.,C+:`5#YXQ4!:Y[5!WS(FC+.,`E+5
MPF+SD8^(,@<N?3*OF/"JZ:<L-[UI?3!M#*[A='@7"E;R4J7YDJ6H#Q\ZL-HK
MLJN/QH\G6-[<C*6G+D&"A)6V?+O3E/GT21ZT!"VI.*VN=2;DW74MQ4TI)2IF
M.OV=M23U"D-A*5#Y@U:[LIN:J<X?.?=699B]\!;3+SWA9V\\9][9GX<^'3EB
MG=HSA)HK2<9A%OL421(9(4)DUM+[^X<]P41[I_-"13\V@#'A0&:***`****`
M****`****`****`**;FN=:6+1%F-RU'.3%8)VMI"2IQU6/A0D<R?U#Q('.HE
M;[4NB5OH;-NU"E*E!/>&.T0/7`=S^K/I0$^T4AZ.U59M8V9-UT[-3,A%1;*P
ME22E8`)2H$`@\QR]17O5NI[-I&S.7344Y$*"V0DN*2I1))P`$I!)/R%`+-%0
M`YVI]$I<4@6W42P#@+3'9P?4?NHJ7-#:SL>M[/\`2>G)OM49*^Z<RA2%-N8!
M*5)(SGF/3R)H!QT4AZOU79='V1R[:BFB'!0M+?>%"EDJ5T`2D$D_(>!/@:AU
MSM3Z*2ZI(MFHE)'+=[.R!\^;N:`GZJN<9M8:BM7:,T[:;=>KA%MC[D$.Q6GU
M);6%.X5E/3F.M6!T-K&R:VLWTIIR9[5$"RTLE"D*0L`$I4%#(."/TU6#CW_C
M2:7_`,Y;OVU`3MQMXK1N%UMMKR[<JYRY[RD-Q^^[D!"`"I95M5T*D#&.>[TI
MT<.]5Q];:,M6H8;*F&IS946E');6E10M.<#.%)4,X&<9IK\=K_I#3VFH4C7E
MD<O$!V6&F6FV$.*0YM4=WO*3CD".1\:=>@IULN>C;/-T_"]AM+\9"XT<MI;+
M:#T&U)(!^1H!P45#VM.T-HG2UY>M:U7&Y2HZU-/^PLI*6EI."DJ6I.3^;D>M
M=6@./6C-:7=JUQ')T"X/JV1V9S(3WRL$D)4A2DYY?A$9R`,T!*]%:I4EF)%=
MD274ML-(+CCBC@)2!DD^@`-0E?.TWH2VSUQHJ;M<T)_?XD=(;)R<@%Q:2>GE
MCUH!"[86J;]IK[DON?O$ZV^T>U]][*\IOO-O<[<XZXW']-3;PXE/S>'NF)<Q
MU;TE^UQ7775G*EK4TDJ43XDDDU4/M+\2M/\`$>%I1_3[DH.1/:^_8DM;%M[^
MYVDX)2<[5=">GA5M.&"TM\+])*6H)2+-$))Z`=PB@'2346<>+O<;1;K4NUSI
M$1;KJPHLK*<X`ZXK?/XR::C2E,L(GS$C]]9:2$'Y;U)/ZL4Q.+>L[3JVT6LV
MQ3R76G7"XR\C:I(P`#RR"#Z$UZ6ATMBNC*<'CX>1Y^JU$'5)0EQ_TG/2[KCV
MG+6\^XIQUR,VM:U'))*0232IFD?2SB6])VA;B@E*8;1)/0`(%,N9QFTVQ)4T
MPU<9:`.3K+*0E7RWJ2K]59%19;.2KCDT]-"N*<W@DVBF[H_6%HU9'<7:7UEU
MD`O,N(VK;SG&?`]/`FE&_7F#8[>N;=)*(\9!P5*!.2>@`',GT%<W7*,MC7'W
M'53BUN3X"AFC-1<[QJTZEY:$P[JM(.-X:0`?4`K!_2*>^E]36O4L%4FTR"ZE
M!"7$*24K;5Y*!_\`SRJ]FGMJ6Z<6D4A?78]L998MT4Q^)_$_3O#F'&<OSDAR
M3*R8\2,WO<="2`HC)"0!N'4C//&<8IB:9[2NE+]?K=:&K9?&I,^2W%96MIHH
M"EJ"4[B',@9(Z`UQ.I.=%<UPG1;9!?FW"2W'B,I+CCSJ@E*$CQ)-0I=.T_H.
M'+6S'8OD]M/1^/%0$*^0<6E7Z0*`>O&CB0UPRTU&NKEN5<G9$I,9N.'NZZI4
MHJ*MJN@3TQSS2MPRU>WKO1-MU"U#7"3,"\L*7O*"A:D$;L#/-.<X\::/%/6>
MC1POLM_UC9)-TL-V6PY'C=PVMUM3C2G$*(*P$D)"AD*_"QS!-.KA;=['>M!V
MJXZ6MQMME>#@CQ2REHMA+BDJRE!*1E25'KXY/6@';140ZX[06BM)7IVUO+N%
MRELG:][`TE2&U?BE2U)!/YN?TUG1':!T3JV[,6QEV?;ILAQ+,=N<R$AY9.`E
M*D*4`23XXH"7:*\NN(::4XXH(0D94HG``\Z@^\=IS0D">Y'BMWBY-H./:(L9
M`;/GCO%I5^J@)RHID<-.)VF^(D60YI^0^)$8)5(BR6BAUH*)`)ZI.<'X5'PS
MBG'J2_6S3=DEW>]RDQ+?%`4Z\L*(3D@#D`2220,`$G-`*E%0-+[4FA6)3K3<
M._R6T*(#S49L)6/,;G$JQ\P#4OW74UKL^EUZ@N\GV.UMLH?<=<23M2K&!@9)
M)*@,#.2:`6J*@.1VI=$-2'&D0-0/MI40'41FDI6/,;G0<'U`/I4H</.(&GM?
MVUV9IR8I[N2E,AEULMNL*(R`I)^OF"4G!P3@T`[**COBAQ=TSPX?8C7I<N1<
M'D!U$.(T%N=V2H;R5%*0,I(^+/D*;_#_`+0.FM;:IA6"WVV\L3I96&U/-M=V
M-J"LY(62.23X&@)D-5^[0_')>C)C^FM,MMN7HM#VB2YG;$WIR`D<LKP4J!R0
M.60>@G'44]5JL%RN*&^]5$C.2`C\8H258^O%?,.9(>F3'I$IYQZ0ZLK<<=45
M*4HG))/B:`<&G[%J3B+J5;%N;E7:[O#O7G77=RMHP"M;BSTY@9)\A4[2^R?.
M3:>\B:H8<N24DEER(4MJ5X`+WDCY[:>MF[/K=K@-QHU];P.:E&-DJ4>IR%?_
M`$8KN/`QSQOK7\E_KULC12UEV8?P9DE?8FTH97Q*J:SX7:QT9'3)U!97F(JE
M$!]M2'FQCS4@D)_VL5T:)XL:TT>\Q]%WN4[$92$)A2W%/1]N<[0@GW?]G!]:
MM&.!KJ>:;ZUGS$7^O27<^S?#N2%"1=(Z5DY+K<3:L_6%<_KI.BI+LV9?P9:-
M\\]J'U&WI/M7.%V.QJK3S6U2L.RK>\4A`\PTO)/A^'_VJ>=$\3M(:U<+.G;T
MQ(E)`)C.)4T[TSR2L`JQ@Y*<BJ[:D[*ET91OTY?X4DC)4U,0IH_(*2%9^L"H
M7UOPXU7HDH5J*T/1V%DA$A"DNM*YX^)!('AR.#Z5D:XX-"DF?2'=Y"LY]*^9
MMFU1<+8L)+GM#!(&Q[*L#T/A_P`*G+AHSI?7C[,"+J)4"\N#`A3(FU2U!.5%
MM064J'7Q"N72M-=5,EESQZ?Z<+++8O"AGU+@9]*,U!OWCG/\NM?R7^O1]XUS
M_+K7\E_KU?J]'YOT.?6+?!]2<=V.M>JB/2G")5BO\*Y*O)<]F7OVM,]V5<L8
MSN/+GS\QFI;WI\Q6>V$(/$)9]#O59*:S)8,T49HKD=0HHHH"EVMTO\5^TTG3
M,Z4\BTQY;D-ML$`MMLH*G@@X^)1;403GF1X"I_D<!.'3UE7;TZ?0SE!2F2V\
MYWR%8^(+).2#SP<CTQRJ$N/.G=0<.>+*.(NG8X7!>>$DK"%+0RYM2AQ+V![J
M7-RL<P3N.""!3CE=JNUJTPHQK%.&H2U@(<V&*'".I4%;RD'GC`)QC/C0#5[/
MLN9H;M`W;145[O;;+D2(CA6D;E>SI=6VO/@<!0./QCY#'5VBVI>O>/MCT;'?
M#3++3;"=_P`*%.?NCB^G78$#'\$4S>SY<95X[2-HN=P(]MFR)LE_"=HWKCO*
M.!X#)Z5O[0DZ?:^T7/GV=3B;C&5%=8+:=Q"TLH(Y8.?E0%F(W`CAPW:DP5:<
M;=3@;GG'W.^40/B*PH$9ZX&!Z57_`(7PW^&':?5IQB0I<"0ZY")R%%QEQ'>,
MYY#"@>[R0!T5CD:>\3M5VE.GD*E6"XF^=V,MME`C*7@9PLJW`=>6TGU/6FSV
M=-/WS7'%B1Q#OK"T16ENOAW:4MNOJ24)0@'JE(4>A.-J<GG0&SCTW.XA]H6U
M:':DEB)'0VUA1]U)4COG'/56P@#\T5-4?@/PY;M*8)TZTXG'-Y;[A>4<==X5
MGZA@>E5FX^7.XV;M)76Y652TW&*Y%=9*$;R"(S7AXC&<CRS4GP>U7:AIT*GV
M&<+\&U#NV2DQE+\#O*MP!Y$^Z?KZT`Q-'=]P@[2_W.6F0N5`DR8]M<[T`J6T
M^&U))Q@;DE2>8'@?.E3CU_C1Z7_SEN_;5ZX$:9O/%#BD[Q"U6TL0X[J9#;J$
M=VAZ0WM2VE`\4("1GGU2`3UKSQZ']M'IC_.6[]M0#Y[:_P#@]LG^M1^R<KCU
M9JR7I3LF:<5`]V1<XK-M#GBVEQM96H>1VH4`?`G-=G;7_P`'MD_UJ/V3E*D3
M0[7$'LQZ?M&2F8BWM282LX`?2E6W=_!.2D^BL^%`5TX4WGA;9(*GM<6.]7F[
M*<RE#:$&,TD9Q@=ZDJ)SSW`CD,#J3S<4[WP[N;D*=PZM5YLMP0Z5/H?"4M*'
M4*1AU92H$#D,#GYCFN\.-:VOA].DZ;XCZ)B3T175#>J$TJ6PK))2=^`XDY!&
M2.1Y$C`"T]Q&^ZC7=OMO"O0E@B=XZE+*Y-K;6]GE^Z+VY#:4\SD9P`230#AX
M[Z\O?WB=#098*96I(:7)KRQ[[B6@TK/+IO*DJ/IR]*>O!C@?HT:"L]TO5N3=
MKA<XK4Q;LA2MK8<;2H(2D$#`SU(SDGGC`'=V@^',_6?#*"^HF9JBRL=\D1TG
M9()2GOTH2!DYV92.N0!XU&7"CM$C25C1I[7%LF._1J4Q8SD-I`<0A`V]VXA2
MD\TX`SG/F,@D@-OM3<-['H.[6.3IIE<6)<D/)7%+BEAM391DI*B3@]YTSX<J
MF;6-Q=A\!M%06E%/MEOAI=]4(82K'^\$?HJ%M6WG4?:'U]`@6:W>RVR'O2R5
MI441T*YEQY8!VE0;2,=,I`&23FSW%+2"[GH6/`LK!4Y;`@QVDGFI"4[-@\S@
MY^8%:='*,;X.?+)PU2E*F2AS.+07#;3PTY`EW*&)LR4PAY:G5DA&](44I`P,
M#/4\^O.F%QET1`TP_$FV='<0Y.6U,%15M6.>1GG@CUZTIZ(XLBRVQNV7^"^X
M(:0PVN.@;TA(`"5I41S&.OZ1XTD7FY77BOJN/"M['L\%GX0KF&DXRI:U`'F>
M@\.@\Z]6F.IKO=EK[/'+[O0\RV5-E*A6NU]1\\1K@_;^#5M;CJVF8RQ%7ZH4
MWDCZP,?77-PFT+I^YZ*CW&Z0$2Y,LN!2G%*PE(648`!P/ASGKSZUW<>FD,:`
MA,,I"6VIC2$ISG`"%@"EK@N<<-;3GS?_`&ZZR=(XZ/=!XS+_`(:5!2U.V7'$
M2,=-Q_N0XV"V0%K,=3@C'<<DMK0%@'U!V_HK?Q<F/ZBXE0--J6&X[#S+"".N
MYX(*E'PY`C'R/G1=ACM#H_TMG]@FE'C7IZ7;;U#U;:&W5NI<2J0I(WAE;8!0
MLC'PX3@D\N0\ZV*<>GKG+VG'@_,R[7T,HKDI<?@/:+POTFU;T1EVM+QV@*><
M6KO%'SR#R/RP*BZQ,G17&E-KAO.&$N0B.4DYW(=0"@'S(*QS]*<<#C;#-E;,
MVW25739S[O;W*E8ZY*L@=/`X]:CVRW65>^*%JND]*0_)N$=9"1A(&Y(2!Z``
M<_$<ZIIJ=1BQ7\L/G[_(O?;2]G1<\K]AO]J2S7"R\6H6J[I"3<;`\J.6VE*.
MQ0:V]XRO`]W<<GUW'&<$!_:/XE\)M;W>QPY>G_HJ\QY#!@%V*E($@+!0E#K1
MS\24_%M!Z<\FE[B'QRL^B];W+36IK1*E04QVE(<C!#A7O3E25H64C'0=3XY%
M5SU_,TKKG6UAC<*;%+M<Z6]L="T=VE3JE#8I*$J4$A/O$D8&/#E7AGL$G]M/
M4\MJ18],QWG&XCC*ILEL`8=._:WGY;5GRR0?`8D+2'9VT-;+'#9O=K^E+J&T
MF3(<DNA)<P-VQ*2D!.<XR,XZFF_VJ>&UTU)8;5?;(PJ;/M319DLM)4MU]M13
M@H2`<[5;E'IR)\J;&@^U%['9VX>L[5)ES60EM,F%MRZ``,K2HC"\CF1RY]!0
M#F[8,"+:N#>G[?;V@S#BW1AAEH$D(0F.\$I&>?(`4FVC4LS2G8U@7"U/JCW!
M1<88=2`2@KFN!1Y]#LW8/@<5U=K"ZM7[@9I>[QD.-L3Y\66VAS&Y*7(KRP#C
M(S@^!KOX=:1.NNR7;[`V\AA^4V\IAU?PI<1,<6G.`3@E.#@9P30%?.%-WX96
M:*\_KZRWJ\7(NDM-QPCV=#8"<93WB"I1.[.<C&.76L<5[QPTO++$KA_9KS:+
MD'`'FI"4".MO!R0`XHA>=O3"<9\:5>'&JK?PWN4FP\2-#1I;:%%PE^"@S&B=
MO(%>`IL@9`]<@X.*7+IQ+CZBU;$M_"OA_96TJV]W[3:6G)"EY^(A.4I2,CGX
M=20.@$@ZYUQ?Y'9.@W6XK`NUW`@R'-@!6VI:TE6.@*VT#/YYQBM/9OX1:2O?
M#6+?M0VU%RF7)3R?W=:MK2$N*;`0`1@DHSGKSY$4N=JQF8QP-AMW-]$B<B;'
M#SK:-J5+VKR0/`9Z4Z>RY_@,TU_ZG_F7:`@*Q1APU[5Z;-I]2FH#LQN(6B=X
M[B0A"^[R>9VE2<'.?=',^/?VF+M-UEQHL^A$N"/#CR(\9!(Y%Z1W>5J\\!20
M/+"O.M&N%?VY\8X/]T[=^P9IU=J305R@WZ%Q'TNATRHA0[-4@;RRMK;W3P3@
M\@![V>0VCS-`2-9>S[PZ@6]AB19/;Y#:`ER2_)=W.*'512%!(SY`"H7[8]U4
MC5VFM-J*FK-$A)E;&ADY6M39Y$X.$MC'YQ\Z<>F.U7`1:F$:GL<U=R0G#CL(
MH+;A_&"5*!3GRR>>:SVJ]'7"],677UBCK?3$B)3+9*0LMM!7>-KV8((!6O?G
M(`P<8R:`9=HU?P%MUG3`>T9J":X4)2[)D-H+KB@!E61(&S/7"<"D;@U>(T'M
M`6T:"1<OH6?(4T8LPI#G<J22H*VJ((1S4#G/N_/+FTSQGX>)L*1J7AW!7>4)
MP5PH$?N7C@>\<X*"?(!5.GLW7_4^J]5RKA!L.G[/I9E:A)5#MX94LE*MC3;@
M'O%)*2KGR!\-PH!D<>X4W2/'7[I]26EN]662M#L=EU1#3J`WL[LD#DI)&<>@
MZ@FI<X<\0N%VN=96M5OLYM>I62HPB]$2RI1[M04$K;)"AM*^2\9\!G%;-=<=
M]/:9U??=+:MLDJ5&CJ;2E4=MM]#J5-H7A:%E//)/F.0JO4V/8];\7K&SPDM$
MVU,K+:E)>!]UU+BE+=`"EA*`C;RY#W>GF!?=:0I"DJ&01@@^-4%X[\))O#J\
MKE0FWG],2'$IBREK"E(64DEI?0A0PK!Q@C'/.0+]CI7//AL3X4B),:0]'?;4
MTXVL92I*A@@B@/G9HO5[,-]B+J`/.6U.07([:5/('+&`2`H#GR.#ZU8C3&DM
M#:FMYF6C7$9UH':I+C(96D^J%J"A^C]-)_%/LQLNJ<G</GD1\)W*MTMU13@`
M\FUD%63@<EG',^]CD*S7.U7K3%Q0U<X,ZUS4^\E$AI32_F`0,BME>OO@E%2X
M>AELT=,VY./'U+@_>OTS^6,/^B^W1]Z[3/Y8P_Z+[=5BTUKSN)S*=1L/2X'1
MPQ5I:>`SU&04GEX8&?,5.6BI/"+5+:\:BNUG?0!EF[2(\?/YJMI2?EG/I6SK
MS_.?RK^S(]'C\-?,QUGA=IG\L8?]']NL'A;ID@@ZRB'(Q^]?;KK3H3ANI*5)
MU?N2KH1<HQ!_]M9^X+AS^5Q_G*-]FNBU-C_$E\ASZ"'@7S#+U!P!T?.C/.6[
M6$./.*5%L[T!M2_#<-QY9Y<L=?'I5?M>:'NNBIB&KB["E,.Y2U*@OI>:<QC/
M3FD\Q\0!\LXJVOW!<.?RN/\`.4;[->'^'W#1UA;;^K`II0PH*N,;!'^[6.RF
M$\R<GG]./X-5=TXX6%C]16OAIJ:VOW-JW:PFN0X2\(;G(9#G='PWCJ4^HR1G
MGRZ6-/"[3(/]^$0?Q7VZIQJ%J$Q?[DS:'5NVYN2XB,XL@E;040@DCEDIQ5L]
M!Z,T-.T58)5UU1W%P>@,./M">PG8HM@D84G(QGH:OI]7=[+FTE[DF1J--5[2
M@LOSP*?WKM,_EC#_`*+[=;8G#+3#,EMU>L6,(5N_<EM(5R\E;CC]%;ON"X<_
ME<?YRC?9H^X+AS^5Q_G*-]FM+OL:P[)?(9U5!<H+YF2T-164#^ZUO_E"/^]*
M;#K;[27&5I<;5S"DG(/UU"1T%PXQ_?<?YRC?9I^:6N6D--65FV0-16Y;#2E*
M"GIS2E$J45$D@@=3X"O-MHC%=AMO].#=7>V^WA>H]**2H&H;-<'2U`NUOE.A
M.XH9D(60,XS@'IDBBL[A)<T:%.+Y,4G&FW6U-NH2M"@4J2H9!!Z@BFM!X<:-
M@7I-VAZ:M;-Q2OO$O(8`*5?C)'0'GU`IV454L(,;1VG(MZ-XCV.W-74K6Z9B
M6$AXJ6"%$KQG)W'/SJL6K_\`'0@?Z9$_8)JW=0S>N#DJX<<(^ODW=A$=I]ET
MPRR2HAML(QNSCGCRH!\S>&^C)]W^E)FF;2]/)W*=7&2=Y/4J'11]2#3L2A*$
MA*4@)`P`/`5D=**`J/?Q_;ML?Z3'_P"215C)W#G1UPNXNLW3=K>N&0KOE,#)
M(Z$CH3\Q3&N7!^7*X\-\01=F$QTNM.>QEDE9VL):QNSCJ,]*F1/2@!*0D`)&
M`.@I$N.DM/7.\-7:X66WR;FT4EN4ZPE3J"DY20K&00>E+E%`)E^T_:-01FX]
M]MD.XL-K[Q#<IE+@2KS`/0\ZZ[?!BVZ$Q#@1VH\1A(0TRVG:E"1T`'@*Z**`
M1-3:3L&J(Z&-0VB'<&V__#[]L**//:>J>@Z&MVGM.V?3D$0[%;8L",.?=L-A
M()\SYGF>M*M%`&!Y4V]3Z%TOJEYM[4%B@3WVQM2ZZT-X'EN'/'I3DHH#BM%J
MM]F@MPK3"CPHC8PEIAL(2/J'R%=F!TK-(]ZER&+A:D,-.*0X^0LI4D!8[IP[
M3D^8!^JB62&\'B[:>L-^=*KC;X<QUH["I205)/7!(YCKT]:4K?`B6Z*F/!CM
M1V$YPVTD)2/J%(%HFN,W?43;4)]X)E)=*TE(2<L,^X"3S5X^6".8R!2DB^,/
M0X;\-IV3[7S:0V`%8`RHJR1M">AST)`ZD9Z2WXVM\"D=G/'$ZKE;(-TCABXQ
M&93(5O"'DA20<8S@_,UL@08MOBHC06&X\=&=K;8VI&3DX'S)KF;N?]DO87H[
MK3I1O0X1EMSS"5>*AXC`..==%PF)A,)=6E2@IUMK`\UK"1^M0JN98V]Q/9SN
M.5=BM*KF+BNW13/!"O:"V-^0,`[NO05W,N-/-)<:6AQL_"I*L@_(UAUT)<:3
M@DN$@8/H3_TIJ:,?>:TU94LLN.H+2R0DI&2%'KDBI4926<\O]_HC,8/"0IJT
MAIY5R,]5GA&65;RYW0R5>?EFNIW3UG=N(GN6V(J:E25!\M#>"D`).>O(`?HK
M0;K'CJN3JDO%3$AMDH*@=SBT-[4H!.`3O2/`9)^=93>W#=56\VN;WR6PZ7`$
M]UM/\//7J,>8/ASJSE-][(2@NXUZHT?I[54=+.HK1#N"4\DJ>;RM/YJOB'U&
MM&DM":8T@'ON;LT2`I[`<6@%2U`>!4HDX],UWJOD?V:(M+;JGY1VMQACO<@X
M5D9P-A^(YP,?+/OZ4V3DPY,=QIYU)4T<@H=P,E(/XP`S@@<NF>>.>UE]R%+`
M\:0KSHW35[D^T7BP6J=((P7)$5"U$>I(S7-9KTXU:YTF>W)6&I<A"<`+4</*
M2EM('4]`!2D[=S&7&]KB/,M/G'?%22AKER#A!Y$G`&,C)'.I<&G@*29XN6F+
M'<[3%M=QM,*3;8NTL1760IMO:DI3M2>0P"0*[+3:X%GM[4"U1&(<)K.QAA`0
MA.22<`=.9)KK"LBD6/J!N3#BOLPY1,E1#+:@E*E)_P#,()]U/3F<=1XD`PDV
M2VES/6I-+6+4T9+&H+3#N#23E(?:"BD^AZCJ>E>M.:;LNF8)AV"V1;?&)W*0
MPV$[CYD]3]=;FKI_9'V*1&>9<*.\0X<%MS^"E7XPZD$#SYCG6AB]>TP7)L6%
M(>C))VE(`4Z!^$A)QD'PZ9\`002PR-R-U^L]JOL-,&^08DZ,I86EF2VE:=PZ
M$`^(Y_KK;:+9`LUO:@6F(Q#A-Y[MAA`0A.25'`'(9))^NM*)+,U4"1&=0\RX
MI12M!R"-JJ3[7<_:(-M>@M2W&'%N##CB5+."L$$D\^8SU\JE09&]&Y_2&G9%
M]%Z?LEO<NX6EP3%,)+H4D`).[&<@`8^5+N*X(=R;DW&9"2VXEV*EM2RK&#O!
M(Q@^&*VP)J)K"G6TJ2E+KC)"L=4+4@_K2:C#+90BW/0ND[I*<DW'35GDR7#E
M;KL-M2U'S)QDTX&$M-H#+(2E+8"0A/X(\!BN"5=D-W%,)B._*?V[G`SM(9'A
MO)(QGG@<R<&M`FN-W28VU"?=6EEMY9&T#GN`2"3S5[I]/,C(S*BV5<UD3+KP
MVT7=KH;E<=,VJ1-)W*=4P/?/FH=%'YYIU--MM-(;:0E#:`$I0D8"0.@`'04F
M.7QA$.*ZEIUQZ3R;BI*>])_"&"0`4_A<^6#6U-R")[422RMEQX$M+R"A9`R4
M@]=P'/!'3H3@XC:R=R$O5>AM+ZM`.H[)"G+2``ZXC#@`\`L84!Z9K;H_2>G-
M+PRC2]KAPF7@%%;`R7!X$K.21]==T*Y&:\XEF))#*5E'?K2$H7RZIYY4/7&#
MX&D[2,]";%88:4*<>5;V5J*1[K:=B0"H^&3T'4\_`$TVL;N.!QT445!8,4F:
MAL-KU%:W;=>X+$V&X#N;=3G'(C(/4'!/,8/.E.B@*WZX[+5FN#SDC2%S=M)P
M2(DA*GVB<#`"RK<D9ZD[^M0?K;@5KK2BD$VQ5X96>3UJ2N0!R_"3M"A\R,>M
M?0"L+(2,J.`.>:`^7L67/LTU:6U.QI#:BE;:DX((\%)/_45(&D.(UKC(0SJN
MRR)_OC=)B2@RM*<\_<*"E1^M-64XOZCX.,QY+FJHUGO-Q<5L6W;TMN3"4D#!
M<0H*1C^$M/2J=ZUF:>FWU][25KEVRV%1V,29/?*`\,<LI^14K\XUWKU-M:Q"
M31RG178\SBF6,L>H.#=VM,Z:NX7:WKBHWJBS%(0\X/)L#(6?#`.?JJ%.(^L[
M9>'U1=*0YL&U#(4J6ZE;K_,$$@#",8Z`G.3S\*:6GK!=M1W!$&Q6Z5/E*('=
MQVRLIR<9..@]3R%6;X7]F)#+K4[7\EF2G&?HR*M6WFG]\=!2<@GHCER^(@XJ
MTM9?)8<V4CI:8O<HHBS@5P@G\1;B9<W?$T]&6`^^4$*?//W&CC!/+WCGW0?$
MX%6L'!K2Z4A(,\`>`>&/_C4A6^!%ML)F';X[4:(RD(:990$(0D=``.0%=.*Y
MUWV5>P\%[*86^VLD:_>;TOYS_P".'V:/O-Z7\Y_\</LU)6*,5UZ[J/&SEU.C
MP(C7[S>E_.?_`!P^S1]YS3'G/_CA]FI*Q1BG7=1XV3U2GPH8=JX5Z8@2%N&,
M_(W)VA+[I('/J,8HI^8HKG+4W2>7)_N=(T5Q6%%!1117$ZA1110!1110`0#U
M`HHHH`HHHH`HHHH`HHHH`HHHH`I(O^YMZV2@TXMF-)+CO=H*U!)9<2"$I!4K
MWE)Y`'KGH#2O6"D$\_*B(8CV)I:)E[6MM:$NS0X@J24[D]PT,C/J"/J--BUV
MI41BWSYC4]#3?M3#C3`<2X@+?4M*]J/>(]T#`!^('H,T_L8-&*NIX*.&1LL1
M6)ESB+BL7'NHZBZ7I2WTA*L%(2$.*!)(63G!'(CK2S?&5/P,(!4IMUI[:!DJ
MV+2O`]3MQ7;C%9ZU5RQAEMN<H2(\],^X,".Q*#3:5+6X]'<9`.``D!:1G.5=
M,XV\^M).G@];-,V7VJ)(W-!:'D);4I;8.XYV@$GF`,`?A9\*=@2!T^5&,YS5
ME/"Q]_?$JX=XT)\9]\SEMQWREV\0GT?N:@2A(C[E8(Z#:K/E@TY&TXN3JMI"
M"R@`XY<BKE_PKLQTK&T5#EE8)4.\:K#<B"[%G+BN+9:=FMNA#94XA+CV]*TI
M`*E`[`,`$G<#X5U/SESKE;1"A/J80\5O//1ULEOW"!@+2"<[L9'(`'/4"G`D
M#&*QL'.HW\<M$;.&$QG(C2D1)<=4.4X\Q<'I;:&EEOOVW%J((<!`!`6?=SGW
M.G,5LN$2'=HIAQF+F\IQ20H2U2FVTI"@23N(R0!D`<\X^=.X@`<O2@#GSYU9
MV<4\$*'<`&!SII.V[NC9KA)$WNX\(Q76H_>!:"H)5NP@[CS0$D`'J">0-._%
M><<ZB,L<"\HY&JB$S<9L=,9NXI:8*EEZ2M].U104A*4K4"3A9][!&`1XUVPK
MOW4-MF9;YC$M"-BF6HSCB`>@"5I248.!X\L\\8-+NT?]:-H/6F[*Q@JH8>4-
MG2K$IFU01-B^SOIE25+;2#A`4XX0!R'+!&#7-I\/VW3EI,B&^2T\Z7D!M16V
M@EW"M@&X\RGD`3SSYT[]HSFLE((YU9SRV\??VPJTE@;33GT?J&Y3GFY)C3F&
M"T6XSCA!0%A04E*24GFGD0,YY=#75I%Q3MG<<*%)W399`4,''M+F,@].6.7A
M6IAYUF]WE'>+<;#*)"$.'(0=I24I'@GW`<>9/G6_2'O:?BNGXI`5)4/`*<6I
M:@/3*CCTQ27!-?#^!'B_W-*-UJNMT??8<7'EK;>2XRRIU0(0ELH*4`JQ[@(.
M,>\>F*4HH#DE]X(4$K2@@K04DC!\",\O*NRC:!TS5-Q.T98MCH<A39#,GN8\
MB>EQ+2G$N)2X\5)6D(PI0PD#`SD+SX5W,MM2;G!]BBW%QIM2G'7I:Y#8:]TA
M.U+A&XDDCEG`SGJ*<P'*@CYU9S;(V)(0;`[]'085IDL24O1F@PE886IMP(&T
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M:![+=MA.,2]9W$W)02"N!&2IIL*Y\BX%;E#IT"/'K5E`,=*R*`1=+Z6L>EH?
LLNGK3#MS)2D+]G:"2YMY`K5U6?51)]:6J**`****`****`****`****`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
